Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 4/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8222390 | 0.81 | ADRA1D (0.64) | ALDH1A1MAPTL3MBTL1ADRA1DADRA1A | |
| SCHEMBL31667423 | 0.78 | ESR1 (0.59) | MEN1KMT2AALDH1A1MAPTENPP2 | |
| SCHEMBL31667351 | 0.77 | KIF11 (0.44) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL31667079 | 0.77 | CA1 (0.66) | MEN1KMT2AMAPTENPP2CACNA1G | |
| SCHEMBL31667432 | 0.77 | ENPP2 (0.51) | MEN1KMT2AENPP2HPGD | |
| SCHEMBL18669025 | 0.75 | CASP3 (0.62) | MEN1KMT2AALDH1A1MAPTALOX15 | |
| SCHEMBL31667420 | 0.74 | KMT2A (0.78) | MEN1KMT2AALDH1A1ENPP2HPGD | |
| SCHEMBL31667405 | 0.73 | CASP3 (0.58) | ESR1CACNA1G | |
| SCHEMBL18379071 | 0.73 | TERT (0.57) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL31667181 | 0.73 | CA9 (0.68) | MEN1KMT2AENPP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | MEN1 2008/4885KMT2A 2737/4885ALDH1A1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.